Evidence map›Paper›PMID 35626127›Full record

ArticleCancers2022

Diagnostic and Prognostic Value of pH- and Oxygen-Sensitive Magnetic Resonance Imaging in Glioma: A Retrospective Study.

Jingwen Yao, Akifumi Hagiwara, Talia C Oughourlian, Chencai Wang, Catalina Raymond, Whitney B Pope, Noriko Salamon, Albert Lai, Matthew Ji, Phioanh L Nghiemphu and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Multimodal Imaging of Hypoxia, Metabolism and pH in Feline Sarcoma Using HyperpolarizedAdvanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Jingwen YaoUCLA Brain Tumor Imaging Laboratory (BTIL), Center for Computer Vision and Imaging Biomarkers, University of California, Los Angeles, CA 90024, USA.ORCID 0000-0002-8828-1841
Akifumi HagiwaraUCLA Brain Tumor Imaging Laboratory (BTIL), Center for Computer Vision and Imaging Biomarkers, University of California, Los Angeles, CA 90024, USA.ORCID 0000-0001-5277-3249
Talia C OughourlianUCLA Brain Tumor Imaging Laboratory (BTIL), Center for Computer Vision and Imaging Biomarkers, University of California, Los Angeles, CA 90024, USA.
Chencai WangUCLA Brain Tumor Imaging Laboratory (BTIL), Center for Computer Vision and Imaging Biomarkers, University of California, Los Angeles, CA 90024, USA.
Catalina RaymondUCLA Brain Tumor Imaging Laboratory (BTIL), Center for Computer Vision and Imaging Biomarkers, University of California, Los Angeles, CA 90024, USA.
Whitney B PopeDepartment of Radiological Sciences, David Geffen School of Medicine, University of California, Los Angeles, CA 90024, USA.
Noriko SalamonDepartment of Radiological Sciences, David Geffen School of Medicine, University of California, Los Angeles, CA 90024, USA.
Albert LaiUCLA Neuro-Oncology Program, University of California, Los Angeles, CA 90024, USA.
Matthew JiUCLA Neuro-Oncology Program, University of California, Los Angeles, CA 90024, USA.
Phioanh L NghiemphuUCLA Neuro-Oncology Program, University of California, Los Angeles, CA 90024, USA.
Linda M LiauDepartment of Neurosurgery, David Geffen School of Medicine, University of California, Los Angeles, CA 90024, USA.
Timothy F CloughesyUCLA Neuro-Oncology Program, University of California, Los Angeles, CA 90024, USA.
Benjamin M EllingsonUCLA Brain Tumor Imaging Laboratory (BTIL), Center for Computer Vision and Imaging Biomarkers, University of California, Los Angeles, CA 90024, USA.
University of California, Los Angeles · US

Funding

Women's CancersP30CA016042 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Samuel Wheeler French · 1985 to 2026
$134.5M
UCLA SPORE in Brain CancerP50CA211015 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Yvonne Yu-Hsuan Chen · 2017 to 2026
$25.2M
Metabolic MRI for quantifying aerobic glycolysis and immune function in gliomasR21CA223757 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ELLINGSON, BENJAMIN M. · 2018 to 2019
$366k
EPA EP-C-15-003NCI NIH HHS 1P50CA211015-01A1NCI NIH HHS 1R21CA223757-01NCI NIH HHS P30 CA016042NCI NIH HHS P50 CA211015NCI NIH HHS R21 CA223757
6 · The paper itself

Abstract

Characterization of hypoxia and tissue acidosis could advance the understanding of glioma biology and improve patient management. In this study, we evaluated the ability of a pH- and oxygen-sensitive magnetic resonance imaging (MRI) technique to differentiate glioma genotypes, including isocitrate dehydrogenase (IDH) mutation, 1p/19q co-deletion, and epidermal growth factor receptor (EGFR) amplification, and investigated its prognostic value. A total of 159 adult glioma patients were scanned with pH- and oxygen-sensitive MRI at 3T. We quantified the pH-sensitive measure of magnetization transfer ratio asymmetry (MTRasym) and oxygen-sensitive measure of R2’ within the tumor region-of-interest. IDH mutant gliomas showed significantly lower MTRasym × R2’ (p < 0.001), which differentiated IDH mutation status with sensitivity and specificity of 90.0% and 71.9%. Within IDH mutants, 1p/19q codeletion was associated with lower tumor acidity (p < 0.0001, sensitivity 76.9%, specificity 91.3%), while IDH wild-type, EGFR-amplified gliomas were more hypoxic (R2’ p = 0.024, sensitivity 66.7%, specificity 76.9%). Both R2’ and MTRasym × R2’ were significantly associated with patient overall survival (R2’: p = 0.045; MTRasym × R2’: p = 0.002) and progression-free survival (R2’: p = 0.010; MTRasym × R2’: p < 0.0001), independent of patient age, treatment status, and IDH status. The pH- and oxygen-sensitive MRI is a clinically feasible and potentially valuable imaging technique for distinguishing glioma subtypes and providing additional prognostic value to clinical practice.

Indexed as

genotypegliomamultiparametric MRIsurvival analysistumor microenvironment

Identifiers

PMID35626127
PMCPMC9139712
OpenAlexW4280488513

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.